News About: Pharm. Industry


CCEJ, “MOHW must suspend health insurance benefits on Novartis’ products”

The Citizens’ Coalition for Economic Justice(CCEJ) has started to call for suspension of health insurance benefits on Novartis’ pharmaceutical products dealt with rebate. In the statement on the 11th, the CCEJ argued...

Pharma industry generates 3 mega blockbuster products recording sales more than KRW 100 billion

It was observed 3 mega blockbuster products, which made annual sales more than KRW 100 billion, were launched last year. Dong-A Pharm’s quasi drug ‘Bacchus’ recorded the largest sales as a single product with KRW 212...

Can’t make orders because of products forcefully pushed in?

While strictly managing regulations related to return and payment for stocked pharmaceutical products, pharmaceutical companies have kept pushing in the products to distribution companies, which has raised a lot of co...

Will rebates impact selection of innovative pharmaceutical company?

Rebates have brought influences on revoking innovative pharmaceutical companies. According to a source from the industry concerned, the company A got revoked as innovative pharmaceutical company for suspension of bus...

‘Top 5’ listed pharmas in R&D ratio to sales were ISU Abxis, Celltrion, Hanmi, Bukwang, Pharmicell

It was observed KOSDAQ listed pharmaceutical companies recorded a 3-times higher average growth rate of R&D expenses than the one in the KOSPI. When it comes to its ratio to sales, KOSDAQ listed pharmaceutical compani...

Hanmi reveals total 23 pipelines consisting of 14 biologics and 9 synthesized drugs

Hanmi Pharm(CEO Sae-Chang Kwon & Jong-Soo Woo) revealed the development status(hereinafter referring to pipeline) of 23 new drugs which are currently being developed now in 2017...

KOSPI records a merchandise sales/sales ratio twice larger than one of KOSDAQ

It was observed the KOSPI listed pharmaceutical companies’ merchandise sales growth rate was much higher than the one of the KOSDAQ. In terms of the merchandise sales ratio to sales, KOSDAQ listed drug companies had a...

Listed pharmas’ annual employee benefits per employee were KRW 6.67 million

It was observed listed pharmaceutical company employees receive employee benefits of approximately KRW 6.67 million last year. In addition, 7 pharmaceutical companies including Daehan New Pharm and Myungmoon Pharm rec...

Korea’s largest place for ‘technology transfers’ will open for pharma & bio industries

The ‘15th Interbiz Bio-Partnering & Investment Forum 2017(hereinafter referring to ‘Interbiz Forum’),’ the Korea’s largest place for technology transfers to generate new market values and secure innovation and product...

Growth rate of export was 20% in KOSDAQ, but negative in KOSPI

While pharmaceutical companies in the KOSDAQ showed a large growth in overseas sales & export on average compared to the year before, KOSPI listed pharmaceutical companies recorded a negative value in the growth ratio...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.